Clinical Trials Browser

Phase 2/3 × INDUSTRY × Cyclophosphamide × Clear all

NCT06193889 2026-01-30

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Phase 2/3 Recruiting

Autoimmune Diseases, Myasthenia Gravis

NCT03699475 2023-09-29

THRIVE

Phase 2/3 Terminated

1 enrolled 9 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute